Font: Financial Modeling Prep • Nov 18, 2026
VolitionRx (NYSE American: VNRX) develops the Nu.Q diagnostic platform. Freedom Broker downgraded VolitionRx to Hold when the stock was priced at $0.19. The shares trade at $0.19, down $0.01, or 5.56%, on volume of 3,018,250 shares.
The downgrade comes as VolitionRx reports progress across its Nu.Q product lines. Its 2026 work includes peer-reviewed validation in sepsis, early-stage cancer detection above 95% in a blinded cohort, and a government-funded sepsis program in France, as highlighted by PRNewsWire.
VolitionRx also expands its Fujifilm agreement to include cats and reduces debt by more than $5 million, as highlighted by PRNewsWire. The company is discussing licenses with more than a dozen diagnostic and liquid biopsy companies worldwide.
VolitionRx says more than 70 patents protect its platform. It aims to co-develop and license the technology in exchange for upfront payments, milestone payments and royalties. The stock’s one-year range is $0.16 to $7.80, and its market capitalization is about $2.27 million.
|
NVDA§>
NVIDIA Corporation
|
$150.96
-2.89%
|
|
LICN§>
Lichen International Limited
|
$0.02
-29.55%
|
|
CHSN§>
Chanson International Holding
|
$0.10
-78.30%
|
|
SOXL§>
Direxion Daily Semiconductor Bull 3X ETF
|
$49.26
0.39%
|
|
SVRE§>
SaverOne 2014 Ltd
|
$0.86
111.01%
|
|
SPDN§>
Direxion Daily S&P 500 Bear 1X ETF
|
$8.90
0.34%
|
|
AKAN§>
Akanda Corp.
|
$4.03
96.59%
|
|
INLF§>
INLIF Limited
|
$0.23
-36.81%
|
|
AES§>
The AES Corporation
|
$15.02
0.33%
|
|
GRAB§>
Grab Holdings Limited
|
$3.14
-1.26%
|